Your browser doesn't support javascript.
loading
Study of breast cancer incidence in patients of lymphangioleiomyomatosis.
Nuñez, Olivier; Román, Antonio; Johnson, Simon R; Inoue, Yoshikazu; Hirose, Masaki; Casanova, Álvaro; de Garibay, Gorka Ruiz; Herranz, Carmen; Bueno-Moreno, Gema; Boni, Jacopo; Mateo, Francesca; Petit, Anna; Climent, Fina; Soler, Teresa; Vidal, August; Sánchez-Mut, José Vicente; Esteller, Manel; López, José Ignacio; García, Nadia; Gumà, Anna; Ortega, Raúl; Plà, María Jesús; Campos, Miriam; Ansótegui, Emilio; Molina-Molina, María; Valenzuela, Claudia; Ussetti, Piedad; Laporta, Rosalía; Ancochea, Julio; Xaubet, Antoni; Pollán, Marina; Pujana, Miguel Angel.
Afiliación
  • Nuñez O; Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, and Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Sinesio Delgado 6, 28029, Madrid, Spain.
  • Román A; Lung Transplant Unit, Department of Pulmonology, Lymphangioleiomyomatosis Clinic, Vall d'Hebron University Hospital, 08035, Barcelona, Catalonia, Spain.
  • Johnson SR; National Centre for Lymphangioleiomyomatosis, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK Division of Respiratory Medicine and Respiratory Research Unit, University of Nottingham, Nottingham, NG7 2UH, UK.
  • Inoue Y; National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, 591-8555, Osaka, Japan.
  • Hirose M; National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, 591-8555, Osaka, Japan.
  • Casanova Á; Department of Pneumology, Henares Hospital, 28882, Madrid, Spain.
  • de Garibay GR; ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Herranz C; ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Bueno-Moreno G; Department of Biochemistry, Autonomous University of Madrid (UAM), Biomedical Research Institute "Alberto Sols" (Spanish National Research Council (CSIC)-UAM), Hospital La Paz Institute for Health Research (IdiPAZ), 28029, Madrid, Spain.
  • Boni J; MD Anderson International Foundation, 28033, Madrid, Spain.
  • Mateo F; ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Petit A; ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Climent F; Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Soler T; Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Vidal A; Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Sánchez-Mut JV; Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Esteller M; Cancer Epigenetics and Biology Program, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • López JI; Cancer Epigenetics and Biology Program, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • García N; Department of Physiological Sciences II, School of Medicine, University of Barcelona, 08908, Barcelona, Catalonia, Spain.
  • Gumà A; Catalan Institution for Research and Advanced Studies (ICREA), 08010, Barcelona, Catalonia, Spain.
  • Ortega R; Cruces University Hospital, BioCruces Research Institute, University of the Basque Country, 48903, Barakaldo, Spain.
  • Plà MJ; ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Campos M; Department of Radiology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Ansótegui E; Department of Radiology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Molina-Molina M; Breast Cancer Functional Unit, Department of Gynecology, University Hospital of Bellvitge, ICO, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Valenzuela C; Breast Cancer Functional Unit, Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Ussetti P; Lung Transplant and Cystic Fibrosis Unit, Hospital Universitario y Politecnico La Fe, 46026, Valencia, Spain.
  • Laporta R; Department of Pneumology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Catalonia, Spain.
  • Ancochea J; Consortium for Biomedical Research in Respiratory Diseases (CIBERES), 28029, Madrid, Spain.
  • Xaubet A; Department of Pneumology, Instituto de Investigación Sanitaria La Princesa, Hospital La Princesa, 28006, Madrid, Spain.
  • Pollán M; Department of Pneumology, University Hospital Clínica Puerta del Hierro, 28222, Madrid, Spain.
  • Pujana MA; Department of Pneumology, University Hospital Clínica Puerta del Hierro, 28222, Madrid, Spain.
Breast Cancer Res Treat ; 156(1): 195-201, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26951504
ABSTRACT
Molecular evidence has linked the pathophysiology of lymphangioleiomyomatosis (LAM) to that of metastatic breast cancer. Following on this observation, we assessed the association between LAM and subsequent breast cancer. An epidemiological study was carried out using three LAM country cohorts, from Japan, Spain, and the United Kingdom. The number of incident breast cancer cases observed in these cohorts was compared with the number expected on the basis of the country-specific incidence rates for the period 2000-2014. Immunohistochemical studies and exome sequence analysis were performed in two and one tumors, respectively. All cohorts revealed breast cancer standardized incidence ratios (SIRs) ≥ 2.25. The combined analysis of all cases or restricted to pre-menopausal age groups revealed significantly higher incidence of breast cancer SIR = 2.81, 95 % confidence interval (CI) = 1.32-5.57, P = 0.009; and SIR = 4.88, 95 % CI = 2.29-9.99, P = 0.0007, respectively. Immunohistochemical analyses showed positivity for known markers of lung metastatic potential. This study suggests the existence of increased breast cancer risk among LAM patients. Prospective studies may be warranted to corroborate this result, which may be particularly relevant for pre-menopausal women with LAM.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Linfangioleiomiomatosis Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Asia / Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2016 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Linfangioleiomiomatosis Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Asia / Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2016 Tipo del documento: Article País de afiliación: España